Bluebird Bio is one of the latest biotech companies moving toward value-based pricing models after announcing in January it would split payments for its gene therapy to cure inherited blood disorder into five yearly installments, according to an article published in the Atlantic.
According to the article, payers would cover the first installment, then move forward depending on how the patient responds to the treatment.
Spark Therapeutics last year also said it would offer a partial refund for its $850,000 gene therapy to cure blindness, Luxturna.
Click here to read the full article on The Atlantic.
